BH3 Mimetics May Have Utility in T Cell Non-Hodgkin Lymphomas

T cell non-Hodgkin lymphomas (T-NHL) are a heterogeneous group of diseases. Most of the treatments used for T-NHL are extrapolated from the treatment of B cell lymphomas and do not take into account any unique biology of T-NHL. A handful of agents are FDA-approved for relapsed and refractory T-NHL, but these agents have response rates on the order of 20-30%. Thus, there is a need for effective, rational therapies in T-NHL.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Elizabeth Brem, Raphael Koch, Rachael Clark, Thomas Kupper, David Weinstock, Anthony Letai Source Type: research